BK Virus Infection Clinical Trial
Official title:
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Verified date | April 2024 |
Source | AlloVir |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.
Status | Completed |
Enrollment | 61 |
Est. completion date | October 20, 2022 |
Est. primary completion date | October 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who had a kidney transplant performed greater than or equal to 28 days prior to enrollment - At least 1 identified, suitably matched Posoleucel (ALVR105) cell line for infusion is available. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. - Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: - Undergone allogeneic hematopoietic cell transplantation - Evidence or history of graft versus host disease (GVHD) or cytokine release syndrome (CRS). - Uncontrolled or progressive bacterial or fungal infections - Known or presumed pneumonia - Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose >0.5 mg/kg/day or equivalent). - Pregnant or lactating or planning to become pregnant. - Weight <40 kg. - Patients who received, or planned to receive abatacept or belatacept, within 3 months of screening |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan Medical Center | Ann Arbor | Michigan |
United States | Piedmont Hospital | Atlanta | Georgia |
United States | John Hopkins Hospital | Baltimore | Maryland |
United States | University of Maryland Medical Center | Baltimore | Maryland |
United States | Harvard Medical School - Brigham & Women's Hospital | Boston | Massachusetts |
United States | Erie County Medical Center | Buffalo | New York |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | University of Virginia | Charlottesville | Virginia |
United States | Northwestern University Transplant Center | Chicago | Illinois |
United States | University of Cincinnati Hospital | Cincinnati | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Baylor University Medical Center | Dallas | Texas |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | Duke University | Durham | North Carolina |
United States | Inova Fairfax Medical Center | Falls Church | Virginia |
United States | UPMC Pinnacle-Harrisburg Hospital | Harrisburg | Pennsylvania |
United States | Indiana University Hospital | Indianapolis | Indiana |
United States | University of Kansas Hospital | Kansas City | Kansas |
United States | Keck Medical Center of USC | Los Angeles | California |
United States | North Shore University Hospital | Manhasset | New York |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Tulane University School of Medicine | New Orleans | Louisiana |
United States | NYU Langone Medical Center | New York | New York |
United States | Weil Medical College - NY Presbyterian Hospital | New York | New York |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Stanford University | Palo Alto | California |
United States | UPMC Montefiore Hospital | Pittsburgh | Pennsylvania |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | University of California Davis Medical Center | Sacramento | California |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | University of California, San Francisco Medical Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
AlloVir |
United States,
Chandraker A, Regmi A, Gohh R, Sharma A, Woodle ES, Ansari MJ, Nair V, Chen LX, Alhamad T, Norman S, Cibrik D, Singh M, Alper A, Jain D, Zaky Z, Knechtle S, Sharfuddin A, Gupta G, Lonze BE, Young JH, Adey D, Faravardeh A, Dadhania DM, Rossi AP, Florescu D, Cardarelli F, Ma J, Gilmore S, Vasileiou S, Jindra PT, Wojciechowski D. Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. J Am Soc Nephrol. 2024 May 1;35(5):618-629. doi: 10.1681/ASN.0000000000000329. Epub 2024 Mar 12. No abstract available. — View Citation
Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs are defined as AEs with a start date and time on or after the first dose of study treatment through the end of study.
Clinically significant changes in vital signs, physical exams, laboratory assessments and electrocardiograms were also reported as TEAEs. |
Day 1 to Week 24 | |
Secondary | Change From Baseline in BK Viral Load | BK viral load was quantitated using polymerase chain reaction assays at the central laboratory. A negative change from baseline represents a reduction in BK viral load. | Baseline and Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02758288 -
BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
|
||
Completed |
NCT01624948 -
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Active, not recruiting |
NCT00684372 -
BK Viremia After Renal Transplantation
|
N/A | |
Recruiting |
NCT06219616 -
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
|
N/A | |
Not yet recruiting |
NCT05264259 -
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
|
||
Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Terminated |
NCT04390113 -
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
|
Phase 3 | |
Withdrawn |
NCT02313844 -
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
|
Phase 1 | |
Completed |
NCT03532971 -
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
|
||
Recruiting |
NCT02479698 -
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
|
Phase 2 | |
Recruiting |
NCT05101213 -
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
|
Phase 1 | |
Completed |
NCT01789203 -
Ciprofloxacin for Prevention of BK Infection
|
Phase 4 | |
Completed |
NCT04693637 -
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Recruiting |
NCT05618275 -
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
|
||
Recruiting |
NCT04542733 -
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient
|
N/A | |
Recruiting |
NCT05042076 -
BK With VST for Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT04294472 -
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
|
Phase 2 |